Tumor-Targeted Split IL12 Receptor Agonists for Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IL12 therapies for cancer treatment suffer from poor therapeutic indices with high toxicity and limited efficacy due to the induction of severe side effects such as IFN-γ and other cytokines.
Innovation Solution
Development of tumor-targeted split IL12 receptor agonists comprising a tumor-targeted IL12Rβ1 agonist and a tumor-targeted IL12Rβ2 agonist, formulated in a single or separate formulations, to enhance therapeutic efficacy and safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IL12 is administered as a therapeutic agent, then anti-tumor efficacy is improved, but systemic toxicity increases due to induction of IFN-γ and other cytokines
Solution Approach 1:
The patent divides the IL12 receptor binding function into two separate components: an IL12Rβ1 binding moiety and an IL12Rβ2 binding moiety. Each component binds to different subunits of the IL12 receptor complex, and their combination enables selective activation of the receptor complex. This segmentation allows for more precise control over IL12 signaling, reducing off-target effects and systemic toxicity while maintaining anti-tumor efficacy.
Solution Approach 2:
The patent incorporates tumor-targeting moieties (such as antibodies or antibody fragments) that specifically recognize and bind to tumor-associated antigens. This localizes the IL12 receptor agonist activity to tumor cells and their microenvironment, ensuring that the therapeutic effect is concentrated where needed while minimizing systemic exposure and associated toxicity.
2Reliability
If high doses of IL12 are administered to overcome toxicity, then anti-tumor efficacy is improved, but safety profile deteriorates
Solution Approach 1:
By segmenting the IL12 receptor binding function into two distinct moieties that target different receptor subunits, the patent achieves more efficient and selective receptor activation. This segmentation allows for lower effective doses compared to conventional IL12 therapy, as the divided binding components work synergistically to activate the full receptor complex, thereby improving the safety profile while maintaining efficacy.
Solution Approach 2:
The patent modifies the pharmacological parameters of IL12 therapy by changing the binding specificity and affinity characteristics. The tumor-targeted split agonists exhibit altered binding kinetics and receptor interaction patterns compared to native IL12, enabling optimized dosing that improves the therapeutic index and safety profile.
3Reliability
If conventional IL12 therapy is used, then immune activation is achieved, but adaptive response leads to progressive decline of IFN-γ blood levels
Solution Approach 1:
The patent employs two separate binding moieties that target different IL12Rβ subunits, creating a more robust and sustained signaling complex. This segmented approach may prevent the adaptive response that occurs with conventional single-agonist therapy, potentially extending the duration of IFN-γ production and immune activation by avoiding the progressive decline associated with repeated administration of native IL12.
Data Source
AI summary
The present disclosure relates to tumor-targeted split IL12 receptor agonists with improved therapeutic profiles.